Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole versus medroxyprogesterone for abnormal uterine bleeding
IRCT20250404065200N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of letrozole and medroxyprogesterone acetate in menstrual disorders (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Reduction in endometrial thickness and Normalization of pathology. Started Aug 2025; status: completed.
02
Drugs
letrozolemedroxyprogesterone acetate
03
Conditions
menstrual disorders
Beyond the preview
Go deeper on IRCT20250404065200N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250404065200N1.